Compared to CAR-T therapy combined with exogenous IL-15 administration, this endogenous secretion strategy offers distinct advantages in maintaining effective drug concentrations in blood and tumor sites, relieving TME-mediated immunosuppression, extending intratumoral effector cell survival, and enabling long-term therapeutic responses to CAR-T cell therapy. This evidence concerns the gene IL15 and neoplasm.